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One of the most exciting scientific accomplishments of this last century is the elucidation of
the human genome sequence. This ambitious project cost hundreds of millions of dollars and
was akin to sending humans to the moon. At the time, some wondered whether we are probing
where no one should. They argued that successfully deciphering the veritable blueprint of life
might forever amputate the intrinsic mysteries of humanity. Yet decades later, it is quite clear
that scientists are still far from understanding the true depth and meaning of the 3.3 billion
base pairs that make up the human genome.
An article published in PLOS Biology by Amaral and colleagues [1] reiterated some of the
challenges associated with exploring this vast treasure trove of human DNA. Rather than sys-
tematically studying and assigning meaning to each gene in the human genome, the global
research enterprise remains focused on a small proportion of the human genome that has
already been studied intensively. This has left thousands of genes in an understudied situation,
even though many of them share associations with human health and disease. We previously
noted [2] that understudied proteins “are less likely to be the subject of scientific curiosity,
which is a reflection of funding patterns and an overall lack of information and molecular
probes.”
Recognizing this fundamental shortcoming, the National Institutes of Health (NIH)
addressed this challenge by launching the Illuminating the Druggable Genome (IDG) program
[2,3] in 2014, with the explicit goal of transforming basic science and drug discovery by shed-
ding light on the “dark genome.” The IDG program, now in its fourth year, has begun the slow
process of reversing human scientific habits, encouraging scientists to apply for funds specifi-
cally to interrogate the “dark genome.” Currently, the IDG aggregates knowledge across all
proteins coded by the human genome, assesses the knowledge state of each protein, and
focuses its experimental efforts on generating new technologies and new data around the dark-
est of druggable genes, specifically those that have the most immediate prospects of improving
human health by means of novel therapies. With success, we hope this effort will demonstrate
the feasibility and value of illuminating understudied proteins, which can then be applied to
additional protein families.
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In addition to the IDG, there are other significant ongoing efforts by the NIH and other
research foundations, including those inside and outside the United States. These include the
Structural Genomics Consortium (SGC), which supports unbiased and systematic research,
helping to deduce the three-dimensional structures of proteins—an important goal for under-
standing basic biology and developing new medicines. In addition, there is the Knockout
Mouse Project (KOMP) and the International Mouse Phenotype Consortium (IMPC) [4,5], an
international consortium whose goal is to generate and characterize a knockout mouse strain
for every gene. The IMPC has partnered with the IDG to identify “dark protein coding genes”
and prioritized the production of orthologous knockout strains. Indeed, the IMPC has already
investigated 47% of the 500 genes that were reported to be understudied by the Amaral and
colleagues article. Further, the Library of Integrated Network-based Cellular Signatures
(LINCS) is helping to illuminate functional connectivity between well-studied and dark genes.
These programs are helping to lead systematic efforts to assign functions to every gene in the
genome and provide high-value fundamental data and resources. As we gain further insight
into the biology of human health and disease, these programs can contribute to the develop-
ment of new therapeutic targets. Instead of looking for keys under the lamppost, where the
light shines, the IDG, SGC, IMPC, and many other programs make it possible to systematically
study the “dark genome.”
We feel impelled to draw attention to extremely valuable data and a growing collection of
community resources (Table 1). As the Amaral article did not include these types of data in
their analyses, it underscores the challenges associated with awareness of a growing collection
of data and resources that bear relevance to understanding the human genome. The fact that
some of these programs have been producing reagents and experimental resources for over a
decade suggests a larger problem with transparency and outreach. Some funded programs are
systematically producing data and resources at a faster pace than researchers can be aware of
them, outpacing the race to understand the rich complexity of human genome. Other pro-
grams stitch data elements from biomedical literature, NIH-funded grants, clinical trials and
worldwide patents, in addition to combining evidence from genome-wide and mouse pheno-
type studies (Pharos, Harmonizome). These imbalances reflect the slow process of the research
enterprise and pose a gentle reminder that the extraordinary accomplishment of the human
genome–sequencing project is really the first step of a long and more arduous journey.
In the larger picture, it’s important to recall that research is anything but systematic and
organized. Like bees to honey, scientists swarm to genes that promise a better understanding
of what makes us human and how to cure disease. However, scientists are also guided by avail-
ability of research support, and as Amaral and colleagues pointed out, there are likely other
systemic barriers to individual-level researchers embarking on study of these neglected pro-
teins. Funded research is often granted to study those genes which have significant pre-existing
knowledge that bolster specific hypotheses. To avoid this “catch 22” situation, the NIH and
Table 1. Links to programs and resources mentioned in this article.
Programs Link
International Mouse Phenotyping Consortium https://www.mousephenotype.org
Illuminating the Druggable Genome Consortium http://druggablegenome.net
Library of Integrated Network-based Cellular Signatures http://lincsproject.org
Structural Genomics Consortium https://www.thesgc.org
Resources and databases
Pharos https://pharos.nih.gov/idg/index
Harmonizome http://amp.pharm.mssm.edu/Harmonizome
https://doi.org/10.1371/journal.pbio.3000067.t001
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funding agencies in Europe, Canada, and elsewhere have established systematic programs
dedicated to helping adjust the organic growth of the research enterprise by making data and
reagents available to investigators. Although these programs are far from perfect and far from
complete, we should continue the increasing trend of funding the “dark genome,” despite the
risky and exploratory nature of exploratory research, accelerating science by shining light on
what makes us human.
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